Original Article

You have full text access to this OnlineOpen article

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion†

  1. Kimmo Porkka MD, PhD1,‡,*,
  2. H. Jean Khoury MD2,
  3. Ronald L. Paquette MD3,
  4. Yousif Matloub MD4,
  5. Ritwik Sinha PhD4,
  6. Jorge E. Cortes MD5

Article first published online: 18 NOV 2009

DOI: 10.1002/cncr.24734

Issue

Cancer

Cancer

Volume 116, Issue 2, pages 377–386, 15 January 2010

Additional Information

How to Cite

Porkka, K., Khoury, H. J., Paquette, R. L., Matloub, Y., Sinha, R. and Cortes, J. E. (2010), Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer, 116: 377–386. doi: 10.1002/cncr.24734

Author Information

  1. 1

    Hematology Research Unit, Biomedicum Helsinki, Helsinki University Central Hospital, Helsinki, Finland

  2. 2

    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

  3. 3

    Department of Medicine, Division of Hematology/Oncology, Ronald Reagan UCLA Medical Center, Los Angeles, California

  4. 4

    Bristol-Myers Squibb, Wallingford, Connecticut

  5. 5

    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas

  1. ‡

    Fax: (011) 358-9-471-71897

*Helsinki University Central Hospital, Biomedicum Helsinki, Hematology Research Unit, P.O. Box 700, FIN-00029 HUCH, Helsinki, Finland

  1. †

    David Dejardin (Bristol-Myers Squibb) provided assistance with statistical analysis.

Publication History

  1. Issue published online: 20 JAN 2010
  2. Article first published online: 18 NOV 2009
  3. Manuscript Accepted: 4 MAY 2009
  4. Manuscript Revised: 21 APR 2009
  5. Manuscript Received: 13 FEB 2009

Funded by

  • Funding for the clinical trial, statistical analysis, and medical writing assistance was provided by Bristol-Myers Squibb (BMS)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (263K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Juan Luis Steegmann, Francisco Cervantes, Philipp Le Coutre, Kimmo Porkka, Giuseppe Saglio, Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia, Leukemia & Lymphoma, 2012, 1

    CrossRef

  2. 2
    Ester M. Orlandi, Barbara Rocca, Anna S. Pazzano, Stefano Ghio, Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia, Leukemia Research, 2012, 36, 1, e4

    CrossRef

  3. 3
    Maria Florencia Tanaka, Hagop Kantarjian, Jorge Cortes, Maro Ohanian, Elias Jabbour, Treatment options for chronic myeloid leukemia, Expert Opinion on Pharmacotherapy, 2012, 13, 6, 815

    CrossRef

  4. 4
    Massimo Breccia, Giuliana Alimena, Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients, BioDrugs, 2011, 25, 3, 147

    CrossRef

  5. 5
    David W. Woessner, Carol S. Lim, Michael W. Deininger, Development of an Effective Therapy for Chronic Myelogenous Leukemia, The Cancer Journal, 2011, 17, 6, 477

    CrossRef

  6. 6
    Jason N. Valent, Charles A. Schiffer, Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib, Leukemia Research, 2011, 35, 1, e1

    CrossRef

  7. 7
    Yasunobu Nagata, Kazuteru Ohashi, Shiomi Fukuda, Noriko Kamata, Hideki Akiyama, Hisashi Sakamaki, Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion, International Journal of Hematology, 2010, 91, 5, 799

    CrossRef

  8. 8
    Hagop Kantarjian, Neil P. Shah, Andreas Hochhaus, Jorge Cortes, Sandip Shah, Manuel Ayala, Beatriz Moiraghi, Zhixiang Shen, Jiri Mayer, Ricardo Pasquini, Hirohisa Nakamae, Françoise Huguet, Concepción Boqué, Charles Chuah, Eric Bleickardt, M. Brigid Bradley-Garelik, Chao Zhu, Ted Szatrowski, David Shapiro, Michele Baccarani, Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia, New England Journal of Medicine, 2010, 362, 24, 2260

    CrossRef

  9. 9
    A. Hochhaus, F. Overkamp, T. Lange, A. Mohr, O. Ottmann, P. Coutre, T. Haferlach, Empfehlungen zur Verlaufskontrolle und Zweitlinientherapie bei der chronischen myeloischen Leukämie (CML), Der Onkologe, 2010, 16, 7, 701

    CrossRef

  10. 10
    E Jabbour, M Deininger, A Hochhaus, Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia, Leukemia, 2010, 25, 2, 201

    CrossRef

  11. 11
    Anupama G Brixey, Richard W Light, Pleural effusions due to dasatinib, Current Opinion in Pulmonary Medicine, 2010, 16, 4, 351

    CrossRef

View Full Article (HTML) Get PDF (263K)